COVID-19 Diagnostics (PCR Testing, Antibody Testing) and Therapy (Immunotherapy, Vaccines, Antiviral, Cell-based, Plasma therapy) Market Opportunity Assessment and Global Forecast to 2025

  • Report ID:MRHC - 104400
  • Pages: 100
  • Jul 2020
  • Formats*: PDF
  • Category: Healthcare
  • Delivery: 2 to 4 Hours

1. Introduction
    1.1. Market Definition
    1.2. Markets Covered
    1.3. Years Considered for the Study
    1.4. Currency
    1.5. Key Stakeholders

2. Research Methodology
    2.1. Research Methodology Steps
    2.2. Secondary and Primary Research Methodology
           2.2.1. Secondary Research
                     2.2.1.1. Key Data from Secondary Sources
           2.2.2. Primary Research
                     2.2.2.1. Key Data from Primary Sources
                     2.2.2.2. Key Insights from Primary Sources
    2.3. Market Size Estimation Methodology
    2.4. Market Forecast Methodology
    2.5. Market Breakdown and Data Triangulation

3. Coronavirus: Epidemiology
    3.1. About Coronavirus
    3.2. Transmission & Symptoms
    3.3. Prevention
    3.4. Epidemiology

4. Executive Summary
    4.1. Introduction
    4.2. Global Economic Impact
    4.3. COVID-19 Response
    4.4. COVID-19 Research Pipeline
    4.5. COVID-19 Pipeline Development Challenges
    4.6. Key Companies

5. Covid-19: Impact on Healthcare Industry
    5.1. Introduction
    5.2. Key Trends & Impact on Healthcare Subsegments
    5.3. Diagnostics
           5.3.1. PCR / Rapid Antigen Testing / Nucleic Acid-Based Tests
                     5.3.1.1. Advantages Offered by PCR Testing in COVID -19 Diagnosis
                     5.3.1.2. Restraints
                     5.3.1.3. Key Companies
           5.3.2. Antibody Testing / Serological Testing
                     5.3.2.1. Advantages Over Molecular Tests
                     5.3.2.2. Use of Antibody Testing for Herd Immunity Analysis and Easing Lock-Down
                     5.3.2.3. Restraints
                     5.3.2.4. Key Companies
    5.4. Therapies
           5.4.1. Vaccines
           5.4.2. Immunotherapies (Antibodies)
                     5.4.2.1. Monoclonal Antibody
                     5.4.2.2. T-Cell Therapy
                     5.4.2.3. Potential Game Changers: Antibodies
                                  5.4.2.3.1. Ilaris (Canakinumab)
                                  5.4.2.3.2. Sylvan (Siltuximab)
                                  5.4.2.3.3. Lenzilumab
                                  5.4.2.3.4. Ultomiris (Ravulizumab-CWVZ)
                                  5.4.2.3.5. Tocilizumab
           5.4.3. Antivirals
                     5.4.3.1. Potential Game Changers
                                 5.4.3.1.1. Chloroquine and Hydroxychloroquine (HCQ)
                                 5.4.3.1.2. Remdesivir
           5.4.4. Cell-Based Therapies
           5.4.5. Other Therapies
                     5.4.5.1. Plasma Therapy
                     5.4.5.2. Devices

6. Geography Impact Assessment
    6.1. Introduction
           6.1.1. Global Virtual Fund-Raising Event to Raise USD 8 Billion for Coronavirus Vaccine
    6.2. North America
           6.2.1. COVID-19 Impact on the U.S. Economy
           6.2.2. Significant R&D Investment by the U.S. Government for COVID-19 Treatment
           6.2.3. High Dependence on the U.S. on Drugs Import Expected to Create Drug Shortages
           6.2.4. Investments by Coalition for Epidemic Preparedness Innovations (CEPI) and Canadian Government
           6.2.5. Canada Announced Investment of USD 192 Million on Vaccine Development as Well as Partnering with Industry and Academics
           6.2.6. Creation of SARS-COV2 Vaccine-Bank by Researchers in Canada
    6.3. Europe
           6.3.1. Economic Impact of COVID-19: European Nations
           6.3.2. European Firms to Lead the COVID-19 Treatment Researches
           6.3.3. U.K. at Forefront in Drug Development Researches to Fight Covid-19
           6.3.4. Partnership of European Pharmaceutical Giants – Sanofi and GSK To Develop COVID-19 Vaccine
           6.3.5. German Vaccine Became the First European MRNA Vaccine to Enter Human Testing
           6.3.6. Growing Interest of Billionaire in German Drug Development for COVID-19
    6.4. APAC
           6.4.1. Economic Impact of COVID-19: APAC
           6.4.2. Asian Countries Leading the Diagnostics Test Commercialization
           6.4.3. India In Favourable Position for Future Production Of COVID-19 Vaccine
           6.4.4. Chinese Lockdown to Negatively Impact the Drugs Supply Chain
    6.5. Rest of the World
           6.5.1. Government Initiatives to Support COVID-19 Medicine Research & Other Drug Supply in Brazil
           6.5.2. Saudi Arabia to Invest USD 2 Billion in Coronavirus Vaccine Development
           6.5.3. Government Initiatives to Support Rapid Development of COVID-19 Therapy in South Africa

7. Competitive Landscape
    7.1. Introduction
    7.2. Agreements/Deals/Partnerships/Collaborations/Joint Ventures
    7.3. R&D Updates
    7.4. Auhrozation / Approvals
    7.5. Donations Made
    7.6. Funding Received
    7.7. Capacity Expansion
    7.8. Other Growth Strategies

8. Company Updates
    8.1. Company Segmentation
    8.2. Diagnostic Companies
           8.2.1. Roche Holding Ag
                     8.2.1.1. About the Firm
                     8.2.1.2. COVID-19 Pipeline
                     8.2.1.3. Recent Developments
           8.2.2. Thermo Fisher Scientific, Inc.
                     8.2.2.1. About the Firm
                     8.2.2.2. COVID-19 Pipeline
                     8.2.2.3. Recent Developments
           8.2.3. Becton, Dickinson and Company
                     8.2.3.1. About the Firm86
                     8.2.3.2. COVID-19 Pipeline
                     8.2.3.3. Recent Developments
           8.2.4. Abbott Laboratories
                     8.2.4.1. About the Firm
                     8.2.4.2. COVID-19 Pipeline
                     8.2.4.3. Recent Developments
           8.2.5. Cepheid (Subsidiary of Danaher Corporation)
                     8.2.5.1. About the Firm
                     8.2.5.2. COVID-19 Pipeline
                     8.2.5.3. Recent Developments
    8.3. Antivirals
           8.3.1. Abbivie Corporation
                     8.3.1.1. About the Firm
                     8.3.1.2. COVID-19 Pipeline
                     8.3.1.3. Recent Developments
           8.3.2. Gilead Sciences, Inc.
                     8.3.2.1. About the Firm
                     8.3.2.2. Covid-19- Pipeline
                     8.3.2.3. Recent Developments
           8.3.3. Eli Lilly And Company
                     8.3.3.1. About the Firm
                     8.3.3.2. Covid-19- Products
                     8.3.3.3. Recent Developments
    8.4. Vaccine Developers
           8.4.1. Moderna, Inc.
                     8.4.1.1. About the Firm
                     8.4.1.2. COVID-19 Pipeline
                     8.4.1.3. Recent Developments
           8.4.2. Novavax, Inc
                     8.4.2.1. About the Firm
                     8.4.2.2. COVID-19 Pipeline
                     8.4.2.3. Recent Developments
           8.4.3. Medicago, Inc
                     8.4.3.1. About the Firm
                     8.4.3.2. COVID-19 Pipeline
                     8.4.3.3. Recent Developments
           8.4.4. Inovio Pharmaceuticals, Inc.
                     8.4.4.1. About the Firm
                     8.4.4.2. COVID-19 Pipeline
                     8.4.4.3. Recent Developments
           8.4.5. GlaxoSmithKline (GSK)
                     8.4.5.1. About the Firm
                     8.4.5.2. COVID-19 Pipeline
                     8.4.5.3. Recent Developments
           8.4.6. Sanofi S.A.
                     8.4.6.1. About the Firm
                     8.4.6.2. COVID-19 Pipeline
                     8.4.6.3. Recent Developments
           8.4.7. Johnson & Johnson
                     8.4.7.1. About the Firm
                     8.4.7.2. COVID-19 Pipeline
                     8.4.7.3. Recent Developments
    8.5. Immunotherapy Firms
           8.5.1. Sorrento Therapeutics, Inc.
                     8.5.1.1. About the Firm
                     8.5.1.2. COVID-19 Pipeline
                     8.5.1.3. Recent Developments
           8.5.2. Astrazeneca Plc
                     8.5.2.1. About the Firm
                     8.5.2.2. COVID-19 Pipeline
                     8.5.2.3. Recent Developments
           8.5.3. Pfizer, Inc.
                     8.5.3.1. About the Firm
                     8.5.3.2. COVID-19 Pipeline
                     8.5.3.3. Recent Developments
           8.5.4. Cti Biopharma Corporation
                     8.5.4.1. About the Firm
                     8.5.4.2. COVID-19 Pipeline
                     8.5.4.3. Recent Developments
           8.5.5. Oncoimmune, Inc.
                     8.5.5.1. About the Firm
                     8.5.5.2. COVID-19 Pipeline
                     8.5.5.3. Recent Developments
    8.6. Cell-Based Therapy
           8.6.1. Athersys, Inc.
                     8.6.1.1. About the Firm
                     8.6.1.2. COVID-19 Pipeline
                     8.6.1.3. Recent Developments
           8.6.2. Cellularity, Inc.
                     8.6.2.1. About the Firm
                     8.6.2.2. COVID-19 Pipeline
                     8.6.2.3. Recent Developments
           8.6.3. Pluristem Therapeutics, Inc.
                     8.6.3.1. About the Firm
                     8.6.3.2. COVID-19 Pipeline
                     8.6.3.3. Recent Developments
    8.7. Plasma Therapy
           8.7.1. Takeda Pharmaceutical Company Ltd
                     8.7.1.1. About the Firm
                     8.7.1.2. COVID-19 Pipeline
                     8.7.1.3. Recent Developments

List of Tables

Table 1 Health & Life Sciences Market Opportunity Assessment Post COVID-19, by Product Type, 2019–2025 ($Million)
Table 2 Industry Trend & Impact Analysis on Healthcare Sub-Sectors Post COVID-19
Table 3 Diagnostics Market Opportunity for COVID-19, by Product Type, 2019–2025 ($Million)
Table 4 Diagnostics Market Opportunity for COVID-19, by Geography, 2019–2025 ($Million)
Table 5 PCR Cycle and Corresponding No. of Target Copies Produced
Table 6 PCR Testing Market Opportunity for COVID-19, by Geography, 2019–2025 ($Million)
Table 7 Antibody Testing Market Opportunity Assessment for COVID-19, by Geography, 2019–2025 ($Million)
Table 8 Therapy Market Opportunity Assessment for COVID-19, by Product Type, 2019–2025 ($Million)
Table 9 Therapy Market Opportunity Assessment for COVID-19, by Geography, 2021–2025 ($Million)
Table 10 Key Vaccine Pipeline For COVID-19 (Non-Exhaustive, As of May 05, 2020)
Table 11 Vaccines Market Opportunity for COVID-19, by Geography, 2021–2025 ($Million)
Table 12 Immunotherapy Pipeline For COVID-19 (Non-Exhaustive, As of May 05, 2020)
Table 13 Immunotherapy Market Opportunity for COVID-19, by Geography, 2021–2025 ($Million)
Table 14 Antiviral Pipeline For COVID-19 (Non-Exhaustive, As of May 05, 2020)
Table 15 Antiviral Market Opportunity for Covid-19, by Geography, 2021–2025 ($Million)
Table 16 Cell-Based Therapy Pipeline for COVID-19 (Non-Exhaustive, As of May 05, 2020)
Table 17 Cell Based Therapy Market Opportunity for COVID-19, by Geography, 2021–2025 ($Million)
Table 18 Plasma Therapies in Pipeline for COVID-19
Table 19 COVID-19 Devices Platforms in Pipeline
Table 20 Other Therapies Market Opportunity for COVID-19, by Geography, 2021–2025 ($Million)
Table 21 Life Sciences Products Market for COVID-19, by Geography, 2019–2025 ($Million)
Table 22 COVID-19 Treatment Investments, by BARDA (U.S.)
Table 23 North America: COVID-19 Health & Life Sciences Market Opportunity, 2019–2025 ($Million)
Table 24 North America: Diagnostics Market Opportunity for COVID-19, 2019–2025 ($Million)
Table 25 North America: Therapy Market Opportunity for COVID-19, by Product Type, 2021–2025 ($Million)
Table 26 Key Economic Indicators: Europe (2019 – 2021)
Table 27 Europe: Health & Life Sciences Market Opportunity for COVID-19, 2019–2025 ($Million)
Table 28 Europe: COVID-19 Diagnostics Market Opportunity, 2019–2025 ($Million)
Table 29 Europe: Therapy Market Opportunity for COVID-19, by Product Type, 2021–2025 ($Million)
Table 30 Key Economic Indicators: Asia (2019 – 2021)
Table 31 APAC: Health & Life Sciences Market Opportunity for COVID-19, 2019–2025 ($Million)
Table 32 APAC: Diagnostics Market Opportunity for COVID-19, 2019–2025 ($Million)
Table 33 APAC: Therapy Market Opportunity for COVID-19, by Product Type, 2021–2025 ($Million)
Table 34 RoW: Health & Life Sciences Market Opportunity for COVID-19, 2019–2025 ($Million)
Table 35 RoW: Diagnostics Market Opportunity for COVID-19, 2019–2025 ($Million)
Table 36 RoW: Therapy Market Opportunity for COVID-19, by Product Type, 2021–2025 ($Million)

List of Figures

Figure 1 Research Methodology 
Figure 2 Market Size Estimation Methodology: Bottom-Up Approach
Figure 3 Market Size Estimation Methodology: Top-Down Approach
Figure 4 Research Design
Figure 5 Data Triangulation Methodology
Figure 6 Global Coronavirus Cases, As of 15 May 2020
Figure 7 GDP Trend Across the U.S., U.K., Germany, China, and India (2019, 2020 (F), and 2021 (F))
Figure 8 COVID-19 Treatment Pipeline, by Development Stage (As of May 2020)
Figure 9 Life Sciences Market Segmentation Impacted by Covid-19
Figure 10 COVID-19 Treatment Pipeline in Development, by type and Development Stage
Figure 11 Vaccine Pipeline, by Category & Development Stage
Figure 12 Immunotherapy / Antibodies Pipeline, by Development Stage (As of May 2020)
Figure 13 Antiviral Pipeline, by Development Stage (As of May 2020)
Figure 14 Cell-Based Therapy Pipeline, by Development Stage (As of May 2020)
Figure 15 Key Economic Indicators: U.S. (2018 To April 2020 & Forecast to 2021)
Figure 16 Key Growth Strategies, by Development & by Company, Feb – May 2020
Figure 17 Key Firms Active in COVID-19 Product Development


The high transmission rate of coronavirus that lead to rapid increase in COVID-19 cases and deaths world-wide triggered the rapid growth in diagnostic and treatment needs. As of 15th May 2020, there existed 4,347,935 confirmed cases and 297,241 deaths due to coronavirus which was declared a pandemic by WHO on March 11, 2020.

Government initiatives supporting rapid development of therapies

To deal with the pandemic, governments across the globe have implemented lockdown or restrictions on movement of people and invested in COVID-19 crisis as well as have been supporting health and life sciences industries in rapid treatment development. Many governments have set up committees that aid in rapid review of therapies being investigated by medical researchers and firms. For instance, FDA announced an accelerated Emergency Use Authorization (EUA) pathway for accelerating emergency use of therapies which could be possible treatment for COVID-19. Several pharmaceutical, biopharmaceutical and biotechnology firms have been granted EUA approval which support further clinical studies on the therapy / candidate being investigated.

Lack of knowledge about novel coronavirus challenging effective treatment development

Key challenges impacting the success rate for therapy development are lack of information on the virus such as biological, genetic information, duration of immunity granted in recovered patients, among others, which is vital to develop a safe & effective treatment option. In future, industry is expecting to face challenges related to production capacity & distribution. Thus, while vaccine development is on-going, manufacturers are also focusing on increasing production capacities.

Key Findings in the COVID-19 Industry Impact Assessment Report:

PCR-testing, Vaccines, and Antiviral are the most explored diagnosis and treatment options for COVID-19

PCR based test is most commonly used in screening patients for COVID-19 primarily due to its effectiveness in early detection which is most critical need for healthcare systems dealing with the rapidly spreading disease. While PCR is effective, it is time-consuming and labor intensive as compared to antibody test which is more suitable for testing presence of antibodies, making it suitable for later stage in the infection cycle. Currently, there are no proven treatments for COVID-19 and potential treatments are underway. Vaccines and antivirals are two of the most explored therapies due to their extensive history in fighting infectious diseases. 

U.S., U.K. – the most affected nations as well as at forefront in terms of research and development for COVID-19

The U.S. and the U.K. are among the most affected nations due to COVID-19. As of 15th May 2020, there existed 1,484,285 and 236,711 confirmed COVID-19 cases in the U.S. and the U.K., respectively (Source: WHO). While the countries are dealing with economic impact of the pandemic, they are also largely involved in research and development efforts for COVID-19 treatment. The government have been providing support to accelerate processes for rapid therapy development as well as monetary support to researches. For instance, in the U.S., the Biomedical Advanced Research and Development Authority (BARDA), a federal agency that funds disease-fighting technology, has stated an investment of nearly USD 1 billion to support coronavirus vaccine development. Similarly, the U.K.’s National Health Services (NHS) announced GBP 24.6 million funding as part of rapid research responses.

Key Players

Some of the key players involved in the COVID-19 product development include Roche Holding AG (Switzerland), Thermo Fisher Scientific, Inc. (U.S.), Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), AbbVie Corporation (U.S.), Gilead Sciences, Inc. (U.S.), Eli Lilly and Company (U.S.), Moderna, Inc. (U.S.), Novavax, Inc. (U.S.), Medicago, Inc. (U.S.), Inovio Pharmaceuticals, Inc. (U.S.), GlaxoSmithKline (U.K.), Sanofi S.A. (France), Johnson & Johnson (U.S.), Sorrento Therapeutics, Inc. (U.S.), AstraZeneca Plc (U.K.), Pfizer, Inc. (U.S.), CTI Biopharma Corporation (U.S.), OncoImmune, Inc. (U.S.), Athersys, Inc. (U.S.), Celularity, Inc. (U.S.), Pluristem Therapeutics (Israel), Takeda Pharmaceuticals Company Ltd (Japan), among others.

Scope of the Report:

COVID-19 Product Pipeline                      

  • Diagnosis
    • PCR Testing
    • Antibody Testing
  • Treatment
    • Vaccines          
    • Immunotherapy
    • Antiviral
    • Cell-based Therapy
    • Other Therapies                                        

COVID-19: Impact on Healthcare Industry   

  • Diagnostics
    • Rapid Test Kits
    • PCR / Rapid Antigen Testing / Nucleic Acid-Based Tests
      • Advantages Offered by PCR Testing in COVID -19 Diagnosis
      • Restraints
      • Key Companies
    • Antibody Testing / Serological Testing
      • Advantages Over Molecular Tests
      • Use of Antibody Testing for Herd Immunity Analysis and Easing Lock-Down
      • Restraints
      • Key Companies
    • Therapies
      • Vaccines
      • Immunotherapies (Antibodies)
      • Monoclonal Antibody
      • T-Cell Therapy
      • Potential Game Changers: Antibodies
        • Ilaris (Canakinumab)
        • Sylvant (Siltuximab)
        • Lenzilumab
        • Ultomiris (Ravulizumab-Cwvz)
        • Tocilizumab
      • Anti-Virals
        • Potential Game Changers
          • Chloroquine and Hydroxychloroquine (HCQ)
          • Remdesivir
        • Cell-Based Therapies
        • Other Therapies
          • Plasma Therapy
          • Devices

COVID-19 Industry Impact Assessment, by Geography        

  • North America
  • Europe
  • Asia-Pacific (APAC)
  • Rest of the World (RoW)

Key Questions Answered:

Coronavirus is a novel virus causing respiratory infection diseases. Common symptoms include fever, dry cough, fatigue, shortness of breath, body-ache, sore throat, diarrhea, conjunctivitis, headache, loss of taste or smell, and skin rashes, among others. Preventive measures include social distancing to keep away from infectious persons and infectious surfaces, frequently washing hands, keep away from touching face, among others. Currently there are no treatment options; however, researches are underway to develop a suitable option.
Globally, a total of 4,347,935 confirmed cases causing 297,241 deaths, worldwide (As of 15 May 2020). The U.K., U.S., Italy, Germany, France, Spain, Brazil, and Iran are among the most affected nations.
PCR-testing and Antibody testing are the most common diagnostics tests available. Potential treatments being investigated include vaccines, immunotherapy, antiviral, cell-based therapy, and other therapies.
Canakinumab (Ilaris) by Novartis, ACE-Mab by Sorrento Therapuetics, Remdesivir anti-viral by Gilead Sciences, and Hydroxychloroquine and chloroquine (HCQ), among others are expected to be the game changing therapies.
The U.S., the U.K., Germany, and India are some of the key nations that are placed in favorable position to arrive at potential solution to COVID-19.
Lack of information on novel coronavirus which is affecting the safety and accuracy aspects of therapies has been creating a challenge in solution development. However, government support in terms of accelerated approval processes as well as public and private funding to support on-going R&D efforts are expected to drive the pipeline
Roche Diagnostics, Thermo Fisher Scientific, Inc., Abbott Laboratories, Acumen Research Laboratories, BioMedomics, CTK Biotech, Biomaxima, Beijing Tigsun Diagnostics Co. Ltd., Moderna, Novavax, Medicago, Inc., GalxosmithKline, Inovio Pharmaceuticals, Johnson & Johnson) / Janssen Pharmaceuticals, Sanofi, Sorrento Therapeutics, AstraZeneca, Pfizer, CTI BioPharma, OncoImmune, Inc., AbbiVie, Gilead Science, Eli Lilly, Athersys, Inc., Celularity, Pluristem Therapeutics, and Takeda Pharmaceutical among others
Partnerships with firms providing complimentary technologies and investment to ramp up production capacity of potential treatment are the key strategies followed by industry players to strengthen their market position.
This website is secure and we do not share your personal information with any third party. Privacy Policy
Tags: Healthcare Medical Technologies
Download Free Sample